CA125 immune complexes in ovarian cancer patients with low CA125 concentrations

Clinical Chemistry

Volumn 56, Issue 12, 2010, Pages 1889-1892

  Cramer, Daniel W ^a   O'Rourke, Dennis J ^a   Vitonis, Allison F ^a   Matulonis, Ursula A ^b   DiJohnson, Daniel A ^a   Sluss, Patrick M ^c   Crum, Christopher P ^a   Liu, Brian C S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; GLUTATHIONE TRANSFERASE A1; IMMUNOGLOBULIN G; NANOPARTICLE;

ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ANTIGEN DETECTION; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; FEMALE; FLUORESCENCE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; RECURRENT CANCER;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; CA-125 ANTIGEN; FEMALE; HUMANS; MEMBRANE PROTEINS; MICE; OVARIAN NEOPLASMS;

CAPRA HIRCUS;

EID: 78649831817     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.153122     Document Type: Article

References (16)

1. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309: 883-7.
2. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001;276: 27371-5.
3. Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, Buller RE. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 2002; 100:59-64.
4. Geisler JP, Miller GA, Lee TH, Harwood RM, Wiemann MC, Geisler HE. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma. J Reprod Med 1996;41:140-2.
5. Buller RE, Berman ML, Bloss JD, Manetta A, DiSaia PJ. Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol Oncol 1992;47: 87-92.
6. Gadducci A, Zola P, Landoni F, Maggino T, Sartori E, Bergamino T, Cristofani R. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol 1995; 58:42-7.
7. Schilthuis MS, Aalders JG, Bouma J, Kooi H, Fleuren GJ, Willemse PH, De Bruijn HW. Serum CA 125 levels in epithelial ovarian cancer: relation with findings at second-look operations and their role in the detection of tumour recurrence. Br J Obstet Gynaecol 1987;94:202-7. (Pubitemid 17036898)
8. Malkasian GD Jr, Knapp RC, Lavin PT, Zurawski VR Jr, Podratz KC, Stanhope CR, et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159: 341-6.
9. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-40.
10. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009;113:775-82.
11. Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S, et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients: from The Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol 2007;104:508-15.
12. Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol 2008;70:431-57.
13. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994;54:2856-60.
14. Hinoda Y, Nakagawa N, Nakamura H, Makiguchi Y, Itoh F, Adachi M, et al. Detection of a circulating antibody against a peptide epitope on a mucin core protein, MUC1, in ulcerative colitis. Immunol Lett 1993;35:163-8.
15. Gourevitch MM, von Mensdorff-Pouilly S, Litvinov SV, Kenemans P, van Kamp GJ, Verstraeten AA, Hilgers J. Polymorphic epithelial mucin (MUC-1)- containing circulating immune complexes in carcinoma patients. Br J Cancer 1995;72:934-8.
16. Noujaim AA, Schultes BC, Baum RP, Madiyalakan R. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43. 13 - evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother Radiopharm 2001;16:187-203.